Elevance Health / Anthem Prior Authorization Guide 2026: Policies, Timelines & Appeals

Elevance Health and Anthem: Who They Cover and How PA Works

Elevance Health (formerly Anthem, Inc.) is the largest Blue Cross Blue Shield-affiliated insurer in the United States by membership. Elevance operates under the Anthem Blue Cross, Anthem Blue Cross Blue Shield, Empire BlueCross BlueShield, HealthKeepers (Virginia), and other BCBS-branded names across 14 states, plus Amerigroup (Medicaid), Simply Healthcare (Medicaid/Medicare), and Wellpoint subsidiary plans. As of 2026, Elevance serves approximately 46 million members across commercial, Medicare Advantage, Medicaid, and federal employee benefit programs.

Prior authorization at Elevance is split between the medical benefit (Elevance/Anthem health plan) and the pharmacy benefit (IngenioRx, Elevance's wholly-owned PBM). Understanding which benefit is applicable and which policy governs is the most important first step before submitting any PA request — routing to the wrong channel causes delays and administrative denials that count against appeal timelines.

Elevance's medical benefit PA policies are published as Medical Policies and Clinical UM Guidelines, available through the Anthem Provider Portal and anthem.com. These are functionally analogous to Aetna's Clinical Policy Bulletins and UnitedHealthcare's Coverage Determination Guidelines: they specify indications, criteria, documentation requirements, and step therapy requirements. The specific policy that applies depends on the member's plan type (commercial, MA, Medicaid) and state.

Elevance Medical Policies and Clinical UM Guidelines

Medical Policies cover drugs, devices, and procedures administered in the medical benefit. Clinical UM Guidelines address utilization management criteria including prior authorization, continued authorization, step therapy, and quantity limits. Both are numbered (e.g., MED.00060 for adalimumab biologic products) and searchable on anthem.com under "Healthcare Professionals > Medical Policies and Clinical UM Guidelines."

Each Medical Policy is organized with a Policy Statement (what is and is not covered), Clinical Criteria (the medical necessity criteria), Background, and References. The Clinical Criteria section is the operational core: it is written in conditional logic specifying what the member must demonstrate and what documentation is required. Denials cite the specific unmet criterion by number. Effective appeals must address that criterion directly using the patient's clinical documentation.

A key distinction at Elevance: Medical Policies are legally binding coverage determinations, while Clinical UM Guidelines describe utilization management procedures that do not always directly govern benefit coverage. For appeals, cite the applicable Medical Policy and its criteria. If a UM Guideline requires step therapy not reflected in the Medical Policy, that tension can be raised in the appeal — step therapy requirements that exceed Medical Policy criteria are challengeable.

IngenioRx Pharmacy Benefit PA

IngenioRx is Elevance's pharmacy benefit manager, handling the pharmacy benefit for most Anthem commercial and Medicare Advantage plans. IngenioRx has its own prior authorization criteria, formulary, and specialty pharmacy network (AcariaHealth is Elevance's specialty pharmacy). PA requests for drugs dispensed through the pharmacy benefit route through IngenioRx, not through Anthem's medical management department.

IngenioRx PA criteria are published at ingeniorx.com and are distinct from Anthem Medical Policies even for the same drug. Specialty drug PA at IngenioRx typically requires: (1) the specific FDA-approved or off-label indication the drug is being prescribed for; (2) relevant clinical parameters (diagnosis confirmation, prior therapy failures, lab values); (3) prescriber specialty in some cases; and (4) a dispensing specialty pharmacy within the IngenioRx network.

Site-of-care requirements are a significant operational issue for Elevance commercial plans. IngenioRx and Anthem have both implemented site-of-care programs that direct certain infused and injectable drugs away from hospital outpatient settings to lower-cost ambulatory settings. If a PA is approved but the site of care is not authorized, the claim may still be denied. Submit site-of-care justification alongside the clinical PA when the drug is typically infused in a hospital outpatient setting.

Prior Authorization Submission Process

Medical benefit PA requests are submitted through the Availity portal (availity.com) or the Anthem Provider Portal. Availity is the primary electronic gateway; many prior authorization workflows are fully electronic with real-time or near-real-time decisions for standard medical necessity criteria. Fax is still accepted for clinical attachment submissions but is significantly slower.

Pharmacy benefit PA requests are submitted through IngenioRx's CoverMyMeds integration, through the dispensing specialty pharmacy, or directly via the IngenioRx provider portal. AcariaHealth specialty pharmacy handles PA submission on behalf of providers for most specialty drugs when AcariaHealth is the dispensing pharmacy.

• ✓ Medical benefit PA portal: Availity (availity.com) — select Elevance/Anthem as the payer; confirm the member's plan type before submission
• ✓ Pharmacy benefit PA: IngenioRx provider portal or through the dispensing specialty pharmacy (AcariaHealth preferred)
• ✓ Fax: provider-specific fax numbers are printed on the member ID card and available through the Anthem Provider Portal by plan type
• ✓ Phone: Anthem commercial provider services lines vary by state; Medicare Advantage has a dedicated MA PA phone line
• ✓ ePA via EHR: Anthem supports electronic PA through Surescripts RTBT and Availity electronic PA — ePA reduces average turnaround by 1-2 days vs fax
• ✓ Required on submission: member ID, ICD-10 diagnosis code(s), CPT/HCPCS code or NDC, prescribing physician NPI, clinical documentation matching the Medical Policy or UM Guideline criteria

PA Decision Timelines by Plan Type

Elevance's PA timelines differ by plan type and reflect the applicable regulatory framework. Confirming the governing timeline before submission is important for managing patient access expectations.

• ✓ Commercial fully-insured (state-regulated): pre-service standard decisions within 15 calendar days (most states); urgent/expedited decisions within 72 hours; some states mandate shorter timelines (California: 5 business days standard, 72 hours expedited)
• ✓ Commercial self-insured/ERISA: pre-service standard within 15 days; urgent within 72 hours; concurrent review decisions within 24 hours under ERISA regulations
• ✓ Medicare Advantage: standard decisions within 14 calendar days (extendable to 28 days with member notification); expedited decisions within 72 hours — these are CMS-mandated and non-negotiable
• ✓ Medicaid (Amerigroup, Simply Healthcare): varies by state contract; generally 3-5 business days standard, 24-72 hours expedited; verify state-specific contracts for exact timelines
• ✓ Concurrent (ongoing) PA for infusions or ongoing specialty drug therapy: Anthem requires periodic reauthorization — intervals are drug-specific (typically every 6-12 months) and outlined in the applicable Medical Policy

Step Therapy Requirements by Drug Class

Elevance's step therapy requirements are embedded in Medical Policies and IngenioRx PA criteria. The following are the most clinically significant step therapy requirements by drug class as of 2026:

• ✓ Rheumatoid arthritis TNF inhibitors (adalimumab, etanercept, certolizumab): Medical Policy MED.00060 typically requires documented DMARD failure (methotrexate ≥12 weeks at therapeutic dose or documented intolerance/contraindication) before biologic TNF approval; Anthem prefers biosimilars (Hadlima, Hyrimoz for adalimumab; Erelzi, Eticovo for etanercept) on the IngenioRx commercial formulary
• ✓ JAK inhibitors (tofacitinib, baricitinib, upadacitinib): require prior TNF inhibitor failure for RA per FDA-boxed warning guidance incorporated into Medical Policy; PsA JAK inhibitors may have similar requirements depending on state and plan type
• ✓ Psoriasis biologics (IL-17, IL-23 agents — secukinumab, ixekizumab, guselkumab, risankizumab): require diagnosis documentation with severity scoring (PASI, BSA, DLQI) and typically prior conventional therapy failure (phototherapy or systemic agent); Anthem has specific PASI/BSA thresholds (generally PASI ≥10 or BSA ≥10%) in its Medical Policy criteria
• ✓ Atopic dermatitis (dupilumab, tralokinumab, lebrikizumab, abrocitinib, upadacitinib): require documented moderate-to-severe disease (IGA ≥3, EASI ≥16, or SCORAD ≥25) and prior adequate trial of topical corticosteroids and/or calcineurin inhibitors; dupilumab typically first-line among biologics on Anthem's formulary
• ✓ GLP-1/GIP agonists (semaglutide/Wegovy, tirzepatide/Zepbound): require BMI ≥30 or ≥27 with at least one weight-related comorbidity; documented lifestyle intervention failure; no concurrent use of other weight-loss medications; Anthem has applied quantity limits and in some plans requires prescriber specialty (endocrinologist, obesity medicine)
• ✓ Oncology (checkpoint inhibitors, CDK4/6 inhibitors, targeted agents): Medical Policies reference NCCN guidelines; Category 1 and 2A recommendations are the primary coverage basis for off-label use; biomarker documentation (PD-L1, MSI-H, TMB, BRCA, EGFR, etc.) must match the FDA label or NCCN indication being invoked
• ✓ MS disease-modifying therapies (natalizumab, ocrelizumab, ofatumumab): require RRMS diagnosis confirmed by MRI, prior interferon or glatiramer failure for most agents; JCV antibody index documentation required for natalizumab

Common Denial Reasons and How to Address Them

Understanding Elevance's most frequent denial categories — and the documentation that resolves each — is the most efficient path to improving first-pass approval rates.

• ✓ Step therapy not completed: the most common denial; submit explicit documentation of the required prior therapy including drug name, dose, dates, and clinical outcome; if contraindicated, attach a signed attestation from the prescriber with clinical rationale
• ✓ Insufficient diagnosis documentation: Anthem's Medical Policies require specific diagnostic criteria (PASI score, HbA1c, disease duration, specialist confirmation); ensure the clinical notes contain the specific metrics the policy requires — a diagnosis code alone is insufficient
• ✓ Non-preferred product without step-through justification: IngenioRx formularies list preferred biosimilars; if a branded product is requested when a biosimilar is preferred, document clinical reason (previous failure, tolerability issue, REMS program, patient-specific factor)
• ✓ Site-of-care mismatch: hospital outpatient infusion may require separate site-of-care authorization in addition to the drug PA; submit site-of-care justification (e.g., REMS requirement, need for on-site monitoring) proactively
• ✓ Missing biomarker documentation: for oncology and precision medicine drugs, the actual laboratory report — not a chart note — must accompany the PA; submit the full pathology or molecular testing report with assay name, result, and date
• ✓ Quantity limit exceeded: document medical rationale for above-limit dosing with relevant clinical parameters; cite FDA label dosing language and the peer-reviewed clinical data supporting the requested dose

Elevance Medicare Advantage Prior Authorization

Elevance operates Medicare Advantage plans in multiple states under the Anthem MediBlue, Amerigroup Medicare, and Simply Healthcare Medicare brands. Elevance MA plans follow CMS prior authorization regulations, which differ significantly from commercial PA rules in ways that favor beneficiaries.

CMS now requires Elevance MA plans to approve PA requests that meet clinical criteria for a minimum of 12 months for chronic conditions (under the 2024 CMS PA final rule). This significantly reduces the burden of annual reauthorization for stable chronic disease patients on ongoing specialty therapy. Document that the condition is chronic and that the patient is clinically stable on the current therapy at each renewal to trigger the 12-month minimum.

Under the CMS interoperability rule (effective 2026 for larger MA plans), Elevance MA plans must support electronic PA and provide real-time PA decisions for standard requests. Non-urgent standard decisions must be issued within 3 business days (a significant tightening from the 14-calendar-day limit); urgent decisions within 24 hours. These tighter timelines increase leverage for providers managing time-sensitive specialty drug access.

For MA oncology denials, cite 42 CFR 422.568(b) in appeals and note that MA plans cannot apply step therapy to cancer chemotherapy agents in a manner inconsistent with NCCN guidelines under CMS guidance. MA plan reviewers are required to consider NCCN guidelines as part of their clinical review standard.

The Elevance Appeal Process

Elevance's internal appeal process for commercial plans has two levels before external review is available. The applicable timelines depend on whether the plan is fully insured (state-regulated) or self-insured ERISA.

• ✓ Level 1 internal appeal (commercial): file within 180 days of denial (ERISA) or the timeframe specified in the denial letter (state-regulated); Anthem must decide within 30 days (pre-service, non-urgent) or 72 hours (urgent) for fully-insured plans
• ✓ Level 2 internal appeal (commercial): available after Level 1 is exhausted; Anthem must again decide within 30 days or 72 hours for expedited; this is the final internal review before external review
• ✓ External review (IRO): after exhausting internal appeals, members have the right to request external review through an independent review organization; most states mandate IRO reviews for medical necessity denials; ERISA plans are also subject to external review under ACA requirements
• ✓ Medicare Advantage Level 1 (Organization Determination): file within 60 days of denial; Anthem MA must decide within 30 days (standard) or 72 hours (expedited)
• ✓ Medicare Advantage Level 2 (Reconsideration): conducted by an independent review entity contracted by CMS (Maximus Federal Services or similar) — not by Anthem; this external entity overturns MA denials at a significant rate when clinical documentation is strong
• ✓ Medicare Advantage Levels 3-5: ALJ hearing (if amount in controversy meets threshold), Medicare Appeals Council, then federal district court — rarely needed for specialty drugs if Level 2 external review is pursued effectively

Peer-to-Peer Review

Peer-to-peer review is available for Elevance medical benefit denials and for many IngenioRx pharmacy benefit denials. The P2P process allows the prescribing physician (or a designated covering physician) to speak directly with the Anthem or IngenioRx medical reviewer who made the denial decision.

Request a P2P immediately upon receiving the denial — ideally within 24-48 hours. The P2P contact number is listed on the denial letter; it can also be obtained by calling Anthem provider services or IngenioRx provider services and requesting to schedule a peer-to-peer. Anthem typically schedules P2P calls within 1-3 business days.

Elevance P2P calls are most effective when the prescribing physician is prepared to cite the specific Medical Policy or UM Guideline criterion that was cited in the denial and explain how the patient's clinical documentation meets it. Providing a concise verbal summary of step therapy completed, relevant diagnostic criteria, and the clinical urgency takes roughly 3-5 minutes and significantly outperforms an unstructured narrative. For oncology cases, having the NCCN category and specific algorithm step available before the call is particularly valuable.

Writing an Effective Elevance Appeal Letter

An effective Elevance appeal letter mirrors the structure of the Medical Policy or IngenioRx PA criteria document that was the basis for denial. Reviewers evaluate appeals against the written policy criteria — demonstrating compliance point-by-point is structurally more persuasive than a general clinical narrative.

• ✓ Open by citing the specific Medical Policy or UM Guideline: "This appeal responds to the denial of [drug] dated [date] under Anthem Medical Policy [MED.XXXXX], Criterion [X]."
• ✓ Address the denial criterion exactly: quote the criterion language from the policy and explain how the clinical documentation meets it
• ✓ Provide complete step therapy documentation: drug name, dose, start/end dates, clinical outcome (or contraindication with rationale) for each required prior therapy
• ✓ Attach the full clinical documentation package: office notes, lab reports, imaging, specialist letters, and any published clinical criteria scores (PASI, EASI, CDAI, etc.)
• ✓ Cite specialty society guidelines: ACR, AAD, ADA, NCCN, or other relevant society recommendations with specific guideline version and recommendation level
• ✓ For biosimilar step-through: document the clinical reason the non-preferred product is medically necessary (prior treatment failure, REMS enrollment requirement, patient-specific clinical factor)
• ✓ Request expedited review if the patient's condition is urgent — clinically document the harm of delay in the appeal letter itself, not just in the check-box
• ✓ Include peer-reviewed clinical trial evidence if the denial is based on insufficient evidence of efficacy: 1-2 RCTs with primary endpoints and the FDA label indication section

Key Medical Policy Numbers to Know

Anthem Medical Policy numbers are assigned per drug class and are stable reference identifiers. The following are the highest-volume specialty drug Medical Policies as of 2026 (exact numbers should be verified at anthem.com as policies are periodically renumbered):

• ✓ MED.00060 — Adalimumab and biosimilars (Humira, Hadlima, Hyrimoz, Cyltezo, etc.) — covers RA, PsA, AS, Crohn's, UC, plaque psoriasis, uveitis
• ✓ MED.00061 — Etanercept and biosimilars (Enbrel, Erelzi, Eticovo) — covers RA, JIA, PsA, AS, plaque psoriasis
• ✓ MED.00109 — Dupilumab (Dupixent) — covers atopic dermatitis, asthma, CRSwNP, EoE, PrP
• ✓ MED.00086 — IL-17 and IL-23 inhibitors (secukinumab, ixekizumab, guselkumab, risankizumab) — covers plaque psoriasis, PsA, AS/nr-axSpA
• ✓ MED.00124 — JAK inhibitors (tofacitinib, baricitinib, upadacitinib, abrocitinib) — covers RA, PsA, UC, atopic dermatitis
• ✓ MED.00099 — GLP-1 and GIP/GLP-1 agonists for obesity (semaglutide/Wegovy, tirzepatide/Zepbound)
• ✓ MED.00103 — Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab) — references NCCN guidelines by indication
• ✓ MED.00072 — Ocrelizumab, natalizumab, and other high-efficacy MS DMTs

Contact Information and Submission Channels

Elevance provider contact information varies significantly by state, plan type, and benefit type. Always confirm the applicable number from the member's ID card or the Anthem Provider Portal before submitting.

• ✓ Medical benefit PA (commercial): Availity (availity.com) is the primary portal; state-specific fax and phone numbers are available on the Anthem Provider Portal by selecting the member's state and plan type
• ✓ IngenioRx pharmacy benefit PA: IngenioRx provider portal (ingeniorx.com) or through AcariaHealth specialty pharmacy (1-800-803-2523)
• ✓ Medicare Advantage PA: Anthem MA provider portal; dedicated MA PA phone lines are printed on the MA member ID card
• ✓ Peer-to-peer requests: listed on the denial letter; or call Anthem provider services and ask for PA peer-to-peer scheduling
• ✓ Appeals: submit to the address or fax on the denial letter; MA appeals should be clearly labeled "Medicare Advantage Organization Determination Appeal"
• ✓ Expedited PA phone (commercial urgent): call the PA phone number on the member's ID card and specify "expedited" or "urgent" at the first prompt — do not use the standard fax queue for urgent cases

Related Resources

• → Prior authorization for biologics
• → Aetna prior authorization guide 2026
• → UnitedHealthcare prior authorization guide 2026
• → Humana prior authorization guide 2026
• → How to write a letter of medical necessity
• → How to appeal an insurance denial step by step
• → Humira (adalimumab) LMN templates
• → Dupixent (dupilumab) LMN templates